

June 18, 2024

Kidswell Bio Corporation

Chiome Bioscience Inc.

Business alliance agreement for co-development of biosimilars

Kidswell Bio Corporation (hereinafter “KWB”), headquartered in Tokyo, Japan and led by President & CEO Shinya Kurebayashi and Chiome Bioscience Inc. (hereinafter “Chiome”), headquartered in Tokyo, Japan and led by President & CEO Shigeru Kobayashi are pleased to announce that the two parties have entered into a business alliance agreement (the “Agreement”) to promote the co-development of new biosimilars by combining the human resources and biopharmaceutical development expertise/experience of the two companies.

Under the Agreement, the two companies will efficiently utilize their respective experience, expertise and human resources and share the development costs of biosimilars in order to expand the business through the co-development of new biosimilars. The companies will share profits from the licensing or transfer to pharmaceutical companies of cell lines and manufacturing processes developed through the collaboration, as well as from the provision of development support and other services to such pharmaceutical companies, with the aim of establishing these as new revenue streams.

With the development of biotechnology, such as use of cells and viruses, biopharmaceuticals have been developed for many diseases that were difficult to treat with small molecule drugs that are chemically synthesized. On the other hand, many Japanese pharmaceutical companies have focused their management resources on R&D activities for small molecule drugs and postponed their efforts on biopharmaceuticals. This has resulted in a delay in the development of biopharmaceutical experts and the accumulation of expertise/experience in biopharmaceutical development, and therefore many biopharmaceuticals are developed and manufactured by overseas companies.

KWB and Chiome have promoted biopharmaceutical R&D since their establishment and have worked to develop experts and accumulate development expertise through their respective biopharmaceutical R&D activities. We have also shared the challenges facing the biopharmaceutical industry in Japan and exchanged views on the development of the industry. Based on the Agreement, the two companies will further enhance mutual understanding through the co-development of biosimilars, while effectively utilizing each other’s biopharmaceutical experts and development expertise to establish best practices in the biopharmaceutical industry and promote new initiatives that will contribute to the development of the industry.

For inquiries regarding this matter, please contact

Kidswell Bio Corporation email: info@kidswellbio.com

Chiome Bioscience, Inc. email: ir@chiome.co.jp